Biotech innovator NeuroScientific Biopharmaceuticals has received the green light from Australia’s drugs regulator to treat ...

A new treatment for early to mild Alzheimer’s disease has been registered with Australia’s pharmaceutical regulator, the ...

Dementia is a condition that results in progressive memory or thinking problems. It's now the most common cause of death in ...

Australian TGA approves additional indication for Telix's Illuccix® to include patient selection for PSMA-Targeted ...

An update from Neuroscientific Biopharmaceuticals Ltd. ( ($AU:NSB) ) is now available. NeuroScientific Biopharmaceuticals has received approval ...

Despite more than 600 reports of "adverse events" for medicinal cannabis in the past three years, the Therapeutic Goods Administration (TGA) is yet to investigate the safety of most medicinal cannabis ...

Regulators focused on pragmatic safety messaging this week, with aligned statements that paracetamol remains appropriate in ...

One of the world's first clinical trials into the potential for psychedelic compound psilocybin to prevent disabling cluster ...

Over the past week, regulatory updates spanned approvals, safety statements and policy shifts. The FDA authorized imlunestrant for ESR1-mutated advanced breast cancer, while Australia’s TGA reversed ...

A new treatment for early to mild Alzheimer’s disease has been registered with Australia’s pharmaceutical regulator, the ...